首页> 外文期刊>Arthritis research & therapy. >Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
【24h】

Incidence of and risk factors for nephrolithiasis in patients with gout and the general population, a cohort study

机译:一项队列研究,痛风患者和一般人群肾结石的发病率和危险因素

获取原文
获取外文期刊封面目录资料

摘要

Background Nephrolithiasis (NL) is known to be associated with gout, although there are few comparative studies on risk and risk factors for NL in gout compared to population cohorts. In this cohort study we investigated: (1) overall incidence of NL in gout (cases) and general population controls; (2) risk and risk factors (common comorbidities and medications) for first-time NL in cases and controls separately. Methods Cases ( n =?29,968) and age-matched and sex-matched controls ( n =?138,678) were identified from the regional healthcare database in western Sweden (VEGA). The analyzed risk factors (comorbidities and current medication use) for first-time NL, and socioeconomic factors were retrieved from VEGA and other national Swedish registers. For cases, follow up began on 1 January 2006 or on the first diagnosis of gout if this occurred later, and for controls on their index patient’s first diagnosis of gout. Follow up ended on death, emigration or 31 December 2012. Incidence rates (IR) per 1000 person-years and hazard ratios (HR) were calculated. The incidence calculations were performed for cases (regardless of prior NL) and their controls. HRs with first occurrence of NL as outcome were calculated only in those without previous NL. Results In cases there were 678 NL events (IR: 6.16 events per 1000 person-years (95% CI: 5.70–6.64) and in controls 2125 NL events (IR 3.85 events per 1000 person-years (95% CI: 3.69–4.02), resulting in an age-sex-adjusted incidence rate ratio of 1.60 (95% CI:1.47–1.74). Point estimates for predictive factors were similar in cases and controls, except for a significant interaction for losartan which increased the risk of NL only in controls (HR?=?1.49 (95% CI: 1.03–2.14). Loop diuretics significantly decreased the risk of NL by 30–34% in both cases and controls. Further significant predictors of NL in gout cases were male sex, diabetes and obesity and in controls male sex and kidney disease. Conclusions The risk (age and sex adjusted) of NL was increased by 60% in cases compared to controls. None of the commonly used medications increased the risk of NL in gout patients.
机译:背景肾结石病(NL)与痛风有关,尽管与人群相比,关于痛风中NL的风险和危险因素的比较研究很少。在这项队列研究中,我们调查了:(1)痛风(病例)和一般人群控制中NL的总体发生率; (2)初次NL的风险和危险因素(常见合并症和药物)分别在病例和对照中。方法从瑞典西部地区医疗数据库(VEGA)中确定病例(n = 29,968),年龄匹配和性别匹配的对照组(n = 138,678)。从VEGA和其他瑞典国家登记册中检索出首次NL的分析风险因素(合并症和当前用药情况)以及社会经济因素。对于这种情况,应于2006年1月1日开始随访,如果随后发生,则从首次诊断为痛风开始,并针对其索引患者的首次诊断为痛风进行控制。随访结束于死亡,移民或2012年12月31日。计算每1000人年的发病率(IR)和危险比(HR)。对病例(无论先前的NL)及其对照进行发病率计算。仅在没有先前NL的患者中计算首次出现NL作为结果的HR。结果在有678个NL事件(IR:每1000人年6.16事件(95%CI:5.70–6.64))和在对照组中有2125个NL事件(IR 3.85事件每1000人年(95%CI:3.69–4.02) ),年龄和性别调整后的发病率比率为1.60(95%CI:1.47–1.74),除了氯沙坦的显着相互作用增加了NL的风险外,病例和对照组中预测因素的点估计值相似。仅在对照组中(HR≥1.49(95%CI:1.03-2.14)。Loop利尿剂在两个病例和对照组中均显着降低了NL的风险,降低了30-34%。痛风病例中NL的其他重要预测指标是男性,结论糖尿病和肥胖症以及对照组男性性别和肾脏疾病结论NL的风险(按年龄和性别调整)与对照组相比增加了60%,没有一种常用药物会增加痛风患者的NL风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号